The Prader-Willi Syndrome (PWS) community in Australia is engaged in a high-stakes advocacy battle to secure access to a new breakthrough treatment for hyperphagia, the life-threatening, insatiable hunger that is a hallmark of the rare genetic disorder.
The treatment, known internationally as Vykat XR (DCCR), has shown promise in clinical trials for managing the excessive eating and behavioral challenges associated with PWS, which affects approximately one in every 17,000 Australians. For families, managing hyperphagia currently relies solely on strict environmental controls, such as locked refrigerators and constant supervision, placing immense strain on caregivers.
The Prader-Willi Research Foundation of Australia (PWRFA) is actively engaging with government bodies to speed up the process for drug availability. This involves navigating a two-step regulatory hurdle: first, gaining approval from the Therapeutic Goods Administration (TGA) for safety and efficacy; and second, securing a subsidy from the Pharmaceutical Benefits Scheme (PBS) to make the expensive medication affordable for Australian families.
Advocacy groups are leveraging international data to expedite the process, but they acknowledge that, historically, even established PWS treatments like growth hormone have taken a decade to receive full subsidized access in Australia. The PWRFA is calling on families and clinicians to help educate decision-makers on the critical, unmet need for treatments that address the core symptoms of PWS, offering hope that this new drug will significantly improve the quality of life for those living with the syndrome.